<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710331</url>
  </required_header>
  <id_info>
    <org_study_id>1501015208.C</org_study_id>
    <nct_id>NCT02710331</nct_id>
  </id_info>
  <brief_title>Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III</brief_title>
  <acronym>THC-ETOH-III</acronym>
  <official_title>Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this study is to characterize the effects of ethanol and cannabinoids
      on simulated driving and related cognition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To study the effects of ethanol clamped at BAC 0.04% (equivalent to consuming approximately 2
      drinks over 1 hour) and oral Dronabinol (10 mg capsule) on driving.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline: Road Tracking Error</measure>
    <time_frame>baseline, +100, +210 mins after start of dronabinol administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline: Biphasic Alcohol Effects Scale (BAES)</measure>
    <time_frame>baseline, +60, +90, +210, +360 mins after start of dronabinol administration</time_frame>
    <description>A scale designed to assess the stimulant and sedative effects associated with alcohol intoxication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline: Visual Analog Scale (VAS)</measure>
    <time_frame>baseline, +60, +90, +210, +360 mins after start of dronabinol administration</time_frame>
    <description>Feeling states associated with alcohol and cannabis intoxication will be measured using this self-report scale of feeling states.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline: Cognitive Test Battery</measure>
    <time_frame>baseline, +120 mins after start of dronabinol administration</time_frame>
    <description>Several computer tasks will be administered to assess alcohol and THC effects on driving related cognition, including:
visual vigilance, visual motor function, attention and working memory, and processing speed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline: Willingness to Drive Scale</measure>
    <time_frame>baseline, +60, +90, +210, +360 mins after start of dronabinol administration</time_frame>
    <description>Subjects will be asked to rate their willingness to drive at their current state in the context of various scenarios including willingness to drive from testing facility to a number of destinations that are different driving distances.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline: Number of Joints Scale</measure>
    <time_frame>baseline, +60, +90, +210, +360 mins after start of dronabinol administration</time_frame>
    <description>Subjects will be asked to rate the number of standard joints that they believe they have been administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline: Number of Drinks Scale</measure>
    <time_frame>baseline, +60, +90, +210, +360 mins after start of dronabinol administration</time_frame>
    <description>Subjects will be asked to rate the number of standard drinks that they believe they have been administered.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cannabis</condition>
  <condition>Alcohol Effect</condition>
  <condition>Driving Under the Influence of Alcohol and Other Drugs</condition>
  <arm_group>
    <arm_group_label>Active THC and Placebo Ethanol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active THC and Active Ethanol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo THC and Active Ethanol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo THC and Placebo Ethanol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Dronabinol</intervention_name>
    <description>10 mg capsule of Dronabinol will be administered orally.</description>
    <arm_group_label>Active THC and Placebo Ethanol</arm_group_label>
    <arm_group_label>Active THC and Active Ethanol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control: no alcohol, administered for ~80 minutes.</description>
    <arm_group_label>Active THC and Placebo Ethanol</arm_group_label>
    <arm_group_label>Placebo THC and Placebo Ethanol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control: Placebo pill (no active cannabinoids) administered orally.</description>
    <arm_group_label>Placebo THC and Active Ethanol</arm_group_label>
    <arm_group_label>Placebo THC and Placebo Ethanol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Ethanol</intervention_name>
    <description>Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.</description>
    <arm_group_label>Active THC and Active Ethanol</arm_group_label>
    <arm_group_label>Placebo THC and Active Ethanol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 21 to 55 years of age (extremes included).

          -  Exposed to cannabis at least once.

          -  Exposed to alcohol at least once.

          -  Able to provide informed consent.

        Exclusion Criteria:

          -  Cannabis naïve

          -  Alcohol naïve

          -  Positive pregnancy screen

          -  Hearing deficits

          -  Sesame oil allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Neeraj Madivala, BA</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>4650</phone_ext>
    <email>neeraj.madivala@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Luddy, BS</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>4549</phone_ext>
    <email>christina.luddy@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Biological Studies Unit, VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neeraj Madivala, B.A.</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>4650</phone_ext>
      <email>neeraj.madivala@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Deepak C. D'Souza, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2016</study_first_submitted>
  <study_first_submitted_qc>March 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Deepak C. D'Souza</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

